Parkinson's disease (PD) is a prevalent neurodegenerative disorder that affects millions of individuals worldwide. This study focuses on the development of Ropinirole loaded chitosan nanoparticles for intranasal delivery, to enhance drug delivery to the brain and improve therapeutic outcomes. Ropinirole is a dopamine agonist used for managing PD symptoms. A Box-Behnken design (BBD) was employed for the optimization of the Ropinirole loaded chitosan nanoparticles. Chitosan, sodium tripolyphosphate (TPP), and Ropinirole were chosen as independent variables. The Ropinirole loaded chitosan nanoparticles evaluated with parameters of particle size, PDI, drug entrapment efficiency, and drug release kinetics. The results revealed the successful formulation of Ropinirole loaded chitosan nanoparticles with desirable physicochemical properties. The FTIR analysis confirmed the compatibility between the drug and excipients. DSC analysis provided insights into the thermal behaviour of the nanoparticles. The developed nanoparticles offer potential advantages for intranasal drug delivery in Parkinson's disease treatment. Intranasal delivery allows direct access to the central nervous system, bypassing the blood-brain barrier and reducing systemic side effects. The sustained release characteristics of the nanoparticles can enhance drug concentration in the brain and reduce dosing frequency. Further studies are warranted to evaluate the efficacy and safety of these Ropinirole loaded chitosan nanoparticles in Parkinson's disease therapy.